Brakiva

Brakiva (ND-121) is a liposomal formulation of topotecan hydrochloride, a semi-synthetic analogue of camptothecin that functions as a topoisomerase I inhibitor. Developed by Access Pharmaceuticals, this formulation utilizes a specialized liposomal delivery system to encapsulate topotecan, aiming to enhance its pharmacokinetic profile by increasing the drug's half-life and improving its accumulation within tumor tissues via the enhanced permeability and retention (EPR) effect. In clinical studies sponsored by the Gynecologic Oncology Group (GOG), specifically trial GOG-9929, Brakiva was evaluated in combination with cisplatin and pelvic radiation therapy for the treatment of locally advanced cervical cancer. The goal of this liposomal approach is to provide a more effective and potentially less toxic alternative to conventional topotecan (Hycamtin) when used as a radiosensitizer in concurrent chemoradiotherapy regimens.

Brand names

Brakiva

Other names

Topotecan hydrochloride liposomesLiposomal topotecan